Effects of Soy Protein on HDL‐C Function, Central Blood Pressure, and Arterial Stiffness: Study Design and Participant Characteristics

Christina Sponsky,Jennifer Fleming,Elaine Krul,Ann Skulas‐Ray,Penny Kris‐Etherton

DOI: https://doi.org/10.1096/fasebj.30.1_supplement.1164.7

2016-04-01

The FASEB Journal

Abstract:Epidemiologic studies report lower rates of cardiovascular disease in Asian populations where soy products are a staple food. Soy protein consumption has been shown to reduce non‐HDL cholesterol and is the richest dietary source of isoflavones (phytoestrogens), a group of bioactive compounds also shown to have potentially favorable effects on CVD risk. We are conducting a randomized, three‐period, double blind crossover study designed to evaluate the effects of soy protein supplementation on HDL function (measured via cholesterol efflux), central blood pressure and indices of arterial stiffness. Healthy males and females 35–60 years of age with systolic blood pressure ≥120 mm Hg and/or diastolic blood pressure ≥80 mm Hg were recruited. The three dietary treatments are: A) 25 g/d soy protein isolate (SPI); B) 50 g/d SPI; and C) 0 g/d SPI (isocaloric carbohydrate control). Participants were free living and followed their habitual diets to which they incorporated the SPI or control powders mixed with milk or water twice daily for 6 weeks each followed by a 2‐week break between treatments. Participants were instructed to keep their diet consistent during treatment periods and asked not to consume any soy containing products other than those provided. Three day dietary records were completed at baseline and during the last week of each treatment to ensure consistency in dietary intake. Participants reported to the diet center weekly to monitor body weight, review consumption logs and collect their soy (or control) powder. Twenty participants are included in the study; 18 have completed all study procedures and 2 will complete their final treatment period by December 2015. Baseline characteristics (mean ± SE) of participants (n=20; 9M & 11F) are as follows: age 51.9 ± 0.72 years, BMI 26.4 ± 0.1 kg/m 2 , systolic blood pressure 129.7 ± 1.9 mm Hg, diastolic blood pressure 82.5 ± 1.1 mm Hg, fasting glucose 88.7 ± 1.0 mg/dL, total cholesterol 197.3 ± 3.3 mg/dl, LDL‐C 120.3 ± 3.0 mg/dL and HDL‐C 55.3 ± 1.4 mg/dL. We hypothesize that consumption of soy protein (in a dose‐dependent manner) will favorably affect HDL particle size, increase HDL‐mediated ex vivo cholesterol efflux and improve central BP and arterial health in this normolipidemic, mildly hypertensive population. Support or Funding Information Sponsored by DuPont Nutrition & Health

cell biology,biochemistry & molecular biology,biology